{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:42:50Z","timestamp":1792669370031,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.inpsyc.2026.100298","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:51:29Z","timestamp":1791316289000},"page":"100298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Memantine in Korean Alzheimer\u2019s disease: A prospective real-world REMIND study"],"prefix":"10.1016","author":[{"given":"Seunghee","family":"Na","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geon Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oh Dae","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Soo","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Nyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak Young","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JaeYeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Young","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee Hyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.inpsyc.2026.100298_bib1","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Nichols","year":"2022","journal-title":"Lancet Public Health"},{"issue":"2","key":"10.1016\/j.inpsyc.2026.100298_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3988\/jcn.2021.17.2.249","article-title":"Prevalence and incidence of dementia in South Korea: a nationwide analysis of the National Health Insurance Service Senior Cohort","volume":"17","author":"Jang","year":"2021","journal-title":"J Clin Neurol"},{"issue":"6","key":"10.1016\/j.inpsyc.2026.100298_bib3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100298_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.inpsyc.2026.100298_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3988\/jcn.2024.0550","article-title":"Eligibility for lecanemab treatment in the Republic of Korea: real-world data from memory clinics","volume":"21","author":"Kang","year":"2025","journal-title":"J Clin Neurol"},{"issue":"11","key":"10.1016\/j.inpsyc.2026.100298_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70875","article-title":"Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations","volume":"21","author":"Jeon","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.inpsyc.2026.100298_bib7","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2147\/NDT.S142839","article-title":"The effects of memantine on behavioral disturbances in patients with Alzheimer\u2019s disease: a meta-analysis","volume":"13","author":"Kishi","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"10.1016\/j.inpsyc.2026.100298_bib8","article-title":"Memantine for dementia","volume":"3","author":"McShane","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"10.1016\/j.inpsyc.2026.100298_bib9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100298_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13195-025-01918-0","article-title":"Dynamic associations of cholinesterase inhibitors and memantine with cognitive trajectories in individuals with Alzheimer\u2019s or mixed dementia: a real-world analysis using the quality registry SveDem","volume":"17","author":"Chen","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"10.1016\/j.inpsyc.2026.100298_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/WAD.0b013e31815a9e10","article-title":"Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients","volume":"22","author":"Vidal","year":"2008","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"10.1016\/j.inpsyc.2026.100298_bib12","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40120-023-00494-5","article-title":"A multicentre, randomised, open-label, prospective study to estimate the add-on effects of memantine as Ebixa\u00ae oral pump (solution) on language in patients with moderate to severe Alzheimer\u2019s disease already receiving donepezil (ROMEO-AD)","volume":"12","author":"Kim","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.inpsyc.2026.100298_bib13","series-title":"The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines","author":"World Health Organization","year":"1992"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100298_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jalz.2007.10.018","article-title":"Prognosis of Alzheimer\u2019s disease today: a two-year prospective study in 686 patients from the REAL-FR Study","volume":"4","author":"Cortes","year":"2008","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.inpsyc.2026.100298_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1192\/bjp.2020.136","article-title":"Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study","volume":"218","author":"Vaci","year":"2021","journal-title":"Br J Psychiatry"},{"issue":"11","key":"10.1016\/j.inpsyc.2026.100298_bib16","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/S2666-7568(23)00193-9","article-title":"Evaluation of clinical benefits of treatments for Alzheimer\u2019s disease","volume":"4","author":"Liu","year":"2023","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100298_bib17","article-title":"Clinically meaningful outcomes in Alzheimer\u2019s disease and Alzheimer\u2019s disease related dementias trials","volume":"11","author":"Stoeckel","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"10.1016\/j.inpsyc.2026.100298_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123289","article-title":"Memantine monotherapy for Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"10","author":"Matsunaga","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100298_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/01.wnl.0000223333.42368.f1","article-title":"Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment","volume":"67","author":"Cummings","year":"2006","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.inpsyc.2026.100298_bib20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease","volume":"366","author":"Howard","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.inpsyc.2026.100298_bib21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","article-title":"Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist\u2014a review of preclinical data","volume":"38","author":"Parsons","year":"1999","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.inpsyc.2026.100298_bib22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100298_bib23","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3233\/ADR-210025","article-title":"Quality of life and caregiver burden of Alzheimer\u2019s disease among community dwelling patients in Europe: variation by disease severity and progression","volume":"5","author":"Froelich","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"issue":"2","key":"10.1016\/j.inpsyc.2026.100298_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3233\/JAD-140360","article-title":"Three-year trajectories of caregiver burden in Alzheimer\u2019s disease","volume":"42","author":"Conde-Sala","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.inpsyc.2026.100298_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1017\/S0714980800012484","article-title":"Reliability, validity and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia","volume":"19","author":"H\u00e9bert","year":"2000","journal-title":"Can J Aging"},{"issue":"2","key":"10.1016\/j.inpsyc.2026.100298_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00004850-200303000-00003","article-title":"Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy","volume":"18","author":"Hartmann","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100298_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40120-017-0067-7","article-title":"A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer\u2019s disease patients","volume":"6","author":"Bent-Ennakhil","year":"2017","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.inpsyc.2026.100298_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JAD-220471","article-title":"Real-world use of symptomatic treatments in early Alzheimer\u2019s disease","volume":"91","author":"Garcia","year":"2023","journal-title":"J Alzheimers Dis"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610226001250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610226001250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:09:05Z","timestamp":1792667345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610226001250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S1041610226001250"],"URL":"https:\/\/doi.org\/10.1016\/j.inpsyc.2026.100298","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Memantine in Korean Alzheimer\u2019s disease: A prospective real-world REMIND study","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.inpsyc.2026.100298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Psychogeriatric Association.","name":"copyright","label":"Copyright"}],"article-number":"100298"}}